The research company Curasight, as planned, reported no revenue in the first quarter with an operating result of DKK -15.3 million (-6.2). The loss before tax amounted to DKK -16.7 million (-6.6). The company’s result after tax was DKK -15.3 million (-5.2), while earnings per share amounted to DKK -0.32 (-0.25). The cash position amounted to DKK 22.1 million at the end of the period, compared with DKK 1.5 million in the corresponding period last year. Curasight says that several important milestones are expected during the rest of 2026, including continued patient recruitment and additional clinical data for both uTREAT and uTRACE. Curasight, MdkkQ1 2026Q1 2025ChangeOperating result-15.3-6.2-146%Result before tax-16.7-6.6-154%Net result-15.3-5.2-195%Earnings per share, DKK-0.32-0.25-28%